Illumina, Inc. $ILMN Shares Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,459 shares of the life sciences company’s stock after buying an additional 3,270 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Illumina were worth $3,015,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital World Investors boosted its position in Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp grew its stake in shares of Illumina by 3.2% during the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after acquiring an additional 190,324 shares in the last quarter. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after acquiring an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after acquiring an additional 130,139 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $192.98 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a one year low of $88.00 and a one year high of $199.14. The company’s 50-day simple moving average is $173.22 and its 200-day simple moving average is $146.03. The stock has a market capitalization of $29.20 billion, a price-to-earnings ratio of 35.09, a PEG ratio of 2.80 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company earned $0.97 earnings per share. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the sale, the insider directly owned 20,953 shares of the company’s stock, valued at approximately $3,771,540. This represents a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last 90 days. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $185.00 in a research report on Wednesday, June 10th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Piper Sandler raised their price target on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Finally, Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $156.88.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.